The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?
Athyros
Vasilios G
VG
Tziomalos
Konstantinos
K
Karagiannis
Asterios
A
Mikhailidis
Dimitri P
DP